Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
26-week randomized trial of insulin degludec/liraglutide vs insulin degludec in type 2 diabetes
2011-002336-72Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2011
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of insulin degludec + liraglutide and insulin degludec in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change from baseline in HbA1c after 26 weeks of treatment. Started Aug 2011; status: completed.
02
Drugs
insulin degludec + liraglutideinsulin degludec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2011-002336-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002336-72.